BLUES will have a significant impact through publications that will be generated during the project, presentation of findings at internationally recognized colloquia, interactions with related projects such as COMBO (101135438), and licensing novel technologies developed. We have already characterised the biomass from C. frondosa and A. corrugata, identified and conducted initial testing of deep-eutectic solvents (DES) for extraction of secondary metabolites from tissue samples. The consortium is also developing and testing novel DES combinations for multi-product biorefinery processes to further improve biomass, and eventually cell biomass, usage – thereby improving the value obtained from the process.
We have also tested the use of scaffolds - made of natural marine-based components such as collagen from fish skin – for the ability to support the attachment and growth of marine sponge cells G. cydonium and G. barretti in a bioreactor of 125mL. This is the first and largest bioreactor cultivation of marine-sponge cells in history, making this a groundbreaking achievement. Given that this achievement has come so early in the project, we aim to build upon this success and further improve the cell culture via media optimisation, scaffold optimisation and increasing and improving the bioreactor scale and functionality.
The first two needs to ensure uptake - further research and demonstration - are the main ones being targeted. There is potential to leverage IPR support, which is being investigated further by the consortium leader, Wageningen University, as the project develops and produces patentable outcomes. It is currently too early in the project to predict what additional measure will be necessary, but this will be monitored throughout the course of the project.